CGH
BEAM icon

Contrarius Group Holdings’s Beam Therapeutics BEAM Stock Holding History

Contrarius Group Holdings’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4M Buy
1,614,538
+1,081,095
+203% +$32.6M 2.55% 13
2026
Q1 		$12.7M Buy
+533,443
New +$14.8M 0.72% 25
2025
Q4 		– Sell
-1,533,269
Closed -$37.2M – 47
2025
Q3 		$37.2M Buy
+1,533,269
New +$30.5M 1.68% 17
2025
Q2 		– Sell
-126,470
Closed -$2.47M – 60
2025
Q1 		$2.47M Buy
+126,470
New +$3.31M 0.17% 49

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Contrarius Group Holdings's BEAM Position: Q2 2026 in Review

Contrarius Group Holdings increased its Beam Therapeutics (BEAM) stake by 203% in Q2 2026, buying an estimated $32.6M and bringing the position to 1,614,538 shares worth $55.4M. The position accounts for 2.55% of the portfolio, ranked #13.

Contrarius Group Holdings first reported a position in BEAM in Q1 2025 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Contrarius Group Holdings held 1,614,538 shares of Beam Therapeutics worth $55.4M as of Q2 2026.
  • Contrarius Group Holdings bought 1,081,095 Beam Therapeutics shares in Q2 2026, an estimated $32.6M.
  • Beam Therapeutics made up 2.55% of Contrarius Group Holdings's portfolio in Q2 2026, its #13 holding.
  • Contrarius Group Holdings first reported a position in Beam Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Contrarius Group Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.